Rumored Trump Move Rattles China-Based Biotech Stocks

Biotech stocks Zai Lab and BeOne Medicines plummeted 9% and 10.5% respectively on Wednesday following reports that President Trump plans an executive order to reduce U.S. access to China-developed drugs, citing national security concerns and aiming to boost domestic production. This potential policy creates a conflict for U.S. biotech investors and major pharmaceutical companies like Pfizer and AstraZeneca, which have increasingly licensed assets from China. Leerink Partners analyst David Risinger suggests such restrictions could backfire, hindering U.S. biopharma development and allowing international competitors to capitalize on the void.

Analysis

Reports of a potential U.S. executive order to limit access to drugs developed in China have introduced significant geopolitical risk into the biotech sector, triggering an immediate and sharp market reaction. China-headquartered biotechs with U.S. listings, Zai Lab (ZLAB) and BeOne Medicines (ONC), saw their shares plummet by 9% and 10.5% respectively, reflecting investor fears over restricted market access and heightened U.S.-China tensions. The proposed policy, aimed at boosting domestic production due to national security concerns, poses a strategic dilemma for major pharmaceutical companies like Pfizer (PFE) and AstraZeneca (AZN). These firms have increasingly relied on licensing lower-cost assets from China to bolster their pipelines, such as PFE's cancer treatment and AZN's GLP-1 weight-loss drug. According to analysis from Leerink Partners, such protectionist measures may backfire, potentially hampering the drug development and pipeline enhancement efforts of U.S. firms. The primary risk highlighted is that international competitors could capitalize on the void, licensing promising Chinese assets and ultimately commercializing them in the U.S. and globally, placing U.S. biopharma at a competitive disadvantage.

Key Decisions for Investors

• Investors should treat China-domiciled biotech stocks like ZLAB and ONC with extreme caution, as their valuations are now highly sensitive to U.S. political and regulatory actions, introducing significant headline risk.
• For large-cap pharma such as Pfizer and AstraZeneca, it is now critical to assess the geopolitical risk embedded in their R&D pipelines and monitor for any strategic shifts away from reliance on Chinese-sourced assets.
• The potential policy may not be a clear tailwind for U.S.-based biotechs; investors should heed analyst warnings that restricting access to Chinese innovation could slow development, potentially disadvantaging firms that lack globally diversified research collaborations.
• Monitor the specific language of any finalized executive order, as details concerning licensing restrictions and government purchasing preferences will be the primary determinants of the financial impact across the sector.